| Literature DB >> 35909986 |
Abstract
Introduction: In an effort to combat SARS-CoV-2 through multi-subunit vaccine design, during studies using whole genome and immunome, ORF10, located at the 3' end of the genome, displayed unique features. It showed no homology to any known protein in other organisms, including SARS-CoV. It was observed that its nucleotide sequence is 100% identical in the SARS-CoV-2 genomes sourced worldwide, even in the recent-most VoCs and VoIs of B.1.1.529 (Omicron), B.1.617 (Delta), B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) lineages, implicating its constant nature throughout the evolution of deadly variants. Aim: The structure and function of SARS-CoV-2 ORF10 and the role it may play in the viral evolution is yet to be understood clearly. The aim of this study is to predict its structure, function, and understand evolutionary dynamics on the basis of mutations and likely heightened immune responses in the immunopathogenesis of this deadly virus.Entities:
Keywords: CTL epitopes; ORF10; SARS-CoV-2; ab initio structural model; genomics; immunoinformatics; miniproteins; mutations and evolution; structure-function
Year: 2022 PMID: 35909986 PMCID: PMC9336178 DOI: 10.1177/11769343221108218
Source DB: PubMed Journal: Evol Bioinform Online ISSN: 1176-9343 Impact factor: 2.031
Figure 1.Schematic flowchart to depict the methodologies used in this study.
Figure 2.Heatmap depicting the predictive impact of substitution mutations for
each residue of ORF10 amino-acid sequence shown at the top label of the
figure. As seen from the scoring bar below the heatmap, dark red square
(score >50) indicates a high score for the strong effect of a
substitution mutation, white-colored square indicates weak signals (−50
Figure 3.(a) ORF10 protein structure modeled using ab-initio modeling webserver QUARK, (b) secondary structure plot of ORF10 protein, motifs: β denotes β-turn, while γ denotes γ-turn, and (c) secondary structure composition and solvent accessibility of residues generated by PredictProtein. Orange and blue colored horizontal bars in the first panel depict helix and strand, respectively. Yellow and blue colored horizontal bars in the second panel depict buried and exposed regions, respectively. Secondary structure composition and solvent accessibility are also shown as pie-charts.
Figure 4.(a) Number of promiscuous HLA-I binding epitopes across SARS-CoV-2 proteins studied. Labeling of protein names in the respective bars starts from the first column of names continuing to the next column, (b) location of selected promiscuous (11 in number) and immunogenic (9 in number, in red fonts) CTL epitopes in ORF10 amino acid sequence predicted through NetCTLpan, PickPocket, and IEDB immunogenicity prediction tools, and (c) location of selected promiscuous (observed through NetMHCIIpan analysis) and immunogenic (observed through both CD4episcore and ITcell analysis) HTL epitopes in ORF10 amino acid sequence.
Substitution mutations in ORF10 amino acid sequence (anchor and secondary anchor positions) as taken from CoV-GLUE (http://cov-glue.cvr.gla.ac.uk/#/home), a database of amino acid variations observed in GISAID EpiCoV™ sequences.
| Mutation | Number of sequences in which this mutation is found |
|---|---|
| P10S | 2693 |
| I4V | 1566 |
| L37F | 1133 |
| S23F | 1024 |
| D31Y | 1004 |
| R24C | 1003 |
| R24L | 774 |
| A8V | 764 |
| T12M | 350 |
| P10L | 331 |
| L17P | 223 |
| F11S | 170 |
| F7L | 145 |
| I4L | 132 |
| F35S | 124 |
| M1I | 115 |
| R24H | 114 |
| A8S | 97 |
| S15G | 97 |
| L17F | 89 |
| D31N | 78 |
| I13L | 73 |
| F11L | 73 |
| I13V | 70 |
| A28S | 68 |
| I27T | 67 |
| Y14C | 65 |
| I13M | 64 |
| Y3C | 61 |
| Y26H | 60 |
| D31H | 59 |
| I4T | 58 |
| F9S | 52 |
| L37I | 45 |
| A8T | 41 |
| V33F | 39 |
| I13T | 38 |
V30L, despite topping the number of sequences, is neither an anchor nor a secondary anchor residue mutation, so it is not included in this table which displays only such mutations.
Immunogenicity ranking of wild type (in red fonts) and mutant (in black fonts) epitopes, wild type immunogenicity scores are taken from Mishra.[2-4]
| Nonamer epitope | Immunogenicity score | FoldX Interaction energy (kcal/mol) for HLA-A*0201 - bound epitopes | FoldX Interaction energy (kcal/mol) for HLA-B*2705 - bound epitopes |
|---|---|---|---|
| YINVFAFPF | 0.28259 | −5.52 | −10.5 |
| Y | 0.28259 | −8.73 | −7.57 |
| QVDVVNFNL | 0.17787 | −11.47 | −8.01 |
| QVDVVNFN | 0.17787 | −3.85 | −2.91 |
| NSRNYIAQV | 0.09731 | 1.91 | −3.4 |
| N | 0.09731 | −3 | −4.76 |
| IAQVDVVNF | 0.09546 | −7.24 | −10.09 |
| IAQV | 0.07026 | −12.52 | −5.99 |
| NS | 0.06301 | −4.22 | −2.3 |
| FPFTIYSLL | 0.05708 | NA | −7.85 |
| F | 0.05708 | −8.88 | −15.62 |
| IAQ | 0.04276 | −9.45 | −9.3 |
Abbreviation: NA, not available as DockTope job failed.
Substitution mutations are in bold and italics.
Figure 5.Number of promiscuous immunogenic HLA-I binding epitopes across SARS-CoV-2 proteins studied clustered with HLA-II binding epitopes. Labeling of protein names in the respective bars starts from the first column of names continuing to the next column.
Names, URLs, and description of prediction tools used throughout this paper.
| S. number | Name | URL | Prediction tool description |
|---|---|---|---|
| Structural analyses | |||
| 1. | QUARK |
| Ab-initio structural modeling |
| 2. | 3Drefine |
| Protein structure refinement server |
| 3. | PDBsum |
| Secondary structure plot |
| 4. | PredictProtein |
| Structural and mutation analyses |
| 5. | PDBeFold |
| Structural similarity search |
| 6. | FoldX in YASARA |
| MHC-peptide interaction energy prediction |
| Sequence-based analyses | |||
| 7. | AllerTOP | Prediction of allergenicity | |
| 8. | AllergenFP | Prediction of allergenicity | |
| 9. | ToxinPred |
| Prediction of toxicity |
| 10. | PHOBIUS TMHMM and MSLVP |
| Subcellular localization prediction tools |
| 11. | NetCTLpan version 1.1 and PickPocket version 1.1 |
| CTL epitope prediction |
| 12. | NetMHCIIpan version 3.2 |
| HTL epitope prediction |
| 13. | IEDB |
| Immunogenicity of CTL epitopes and clustering prediction |
| 14. | CD4episcore |
| Immunogenicity of HTL epitopes |
| 15. | ITcell |
| Immunogenicity of HTL epitopes |
| 16. | DockTope |
| MHC-peptide modeling |